))
Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D.
Manage episode 499986146 series 3677839
Content provided by Tyler Menichiello. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tyler Menichiello or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
5 episodes
Share
